SUPN

SUPERNUS PHARMACEUTICALS, INC. SUPN

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,031 of 2,931

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Feb 14, 2027.

Revenue

$226.77M

Quarter to Sep 30

Net income

$20.91M

Quarter to Sep 30

Free cash flow

$6.38M

Quarter to Sep 30

Operating margin

9.3%

Quarter to Sep 30

Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2026
EDGAR

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

Operating Margin

Q3 2026
EDGAR

ROIC

Q3 2026
EDGAR

Free Cash Flow

Q3 2026
EDGAR

Debt/Equity

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SUPN

Earnings Per Share

13fpro.ai/company/SUPN

Loading ratio trend…

SUPN key financials by period

Reported revenue, net income and operating margin by fiscal year, from SUPERNUS PHARMACEUTICALS, INC.'s annual filings on SEC EDGAR.

SUPERNUS PHARMACEUTICALS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$719.0M$-38.5M-8.7%
FY 2024$1.2B$7.0M3.2%
FY 2023$1.1B$-126.0M-13.9%
FY 2022$901.0M$-44.0M-9.0%
FY 2021$579.8M$53.4M14.8%
FY 2020$520.4M$127.0M33.4%
Source: SUPN filings on SEC EDGAR →

SUPN.R1356576 insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About SUPERNUS PHARMACEUTICALS, INC. (SUPN): stock profile, AI score and financials

SUPERNUS PHARMACEUTICALS, INC. (SUPN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SUPN at 42.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,031 of 2,931 stocks — the bottom half of the AI-ranked universe. SUPN scores in the top quartile across balance sheet strength (93.8), profitability (87.0). Areas of concern include institutional flow (0.1) and revenue growth (5.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), SUPERNUS PHARMACEUTICALS, INC. reports quarterly revenue of $226.8M, net income of $20.9M, an operating margin of 9.3%. Top institutional holders of SUPN by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. SUPN trades on the Nasdaq exchange and files with the SEC under CIK 1356576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SUPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUPERNUS PHARMACEUTICALS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1356576 →